RNA Based Therapeutic Market Trend 2023: Anticipated Growth to Reach $25.12 Billion by 2030 | 17.6% CAGR

According to the report, the global RNA based therapeutics industry was estimated at $4.93 billion in 2021, and is anticipated to hit $25.12 billion by 2030, registering a CAGR of 17.6% from 2021 to 2030. The study analyzes the important strategies, drivers, competition, market dynamics, size, and important investment regions.

Key Takeaways:

Market Growth: The RNA-based therapeutic market has witnessed substantial growth and is expected to continue expanding in the coming years. This growth can be attributed to increasing investment in research and development, technological advancements, and a growing understanding of RNA-based therapeutics.

mRNA Therapeutics: Messenger RNA (mRNA) therapeutics have gained significant attention and have emerged as a promising approach in the field. mRNA vaccines, such as the ones developed for COVID-19, have demonstrated their efficacy and have paved the way for further exploration of mRNA-based treatments for various diseases, including cancer, infectious diseases, and genetic disorders.

RNA Interference (RNAi) Therapeutics: RNA interference is a mechanism that regulates gene expression. RNAi therapeutics utilize small interfering RNA (siRNA) molecules to silence specific genes involved in disease processes. RNAi-based drugs have shown potential in treating various diseases, particularly in the field of rare genetic disorders and liver-related diseases.

Therapeutic Applications: RNA-based therapeutics hold promise for a wide range of diseases. They have shown potential in treating genetic disorders, cancer, infectious diseases, cardiovascular diseases, neurodegenerative diseases, and autoimmune disorders. The versatility of RNA-based therapies allows for targeted and personalized treatment approaches.

Market Players: Several pharmaceutical and biotechnology companies are actively involved in the development and commercialization of RNA-based therapeutics. Companies like Moderna, BioNTech, Alnylam Pharmaceuticals, and Arrowhead Pharmaceuticals have made significant advancements in this field and have gained attention for their innovative approaches.

Download Sample Report- https://www.alliedmarketresearch.com/request-sample/546

Market Drivers:

Growing Demand for Targeted and Personalized Medicine: RNA-based therapeutics offer the potential for targeted and personalized treatments. They can be designed to specifically target disease-causing genes or proteins, providing a more precise approach compared to traditional therapies. The increasing demand for personalized medicine and targeted therapies is driving the growth of the RNA-based therapeutic market.

Advancements in RNA Delivery Technologies: Efficient delivery of RNA molecules to target cells or tissues is crucial for the success of RNA-based therapeutics. Recent advancements in delivery technologies, such as lipid nanoparticle formulations and viral vectors, have improved the efficiency and specificity of delivering RNA molecules to the desired sites. These advancements have expanded the potential applications of RNA-based therapies and have contributed to market growth.

Market Segmentation:

Therapeutic Modality:

• mRNA Therapeutics: This segment includes mRNA-based therapies that utilize synthetic mRNA molecules to encode proteins of interest or trigger specific cellular responses.
• RNA Interference (RNAi) Therapeutics: This segment comprises therapies based on RNA interference, which involve the use of small interfering RNA (siRNA) molecules to silence or modulate the expression of disease-causing genes.
• Antisense Oligonucleotides (ASOs): ASOs are short synthetic DNA or RNA molecules that bind to specific RNA targets, influencing gene expression or protein production. This segment includes therapies based on ASOs.

Application:

• Oncology: This segment includes RNA-based therapeutics used in the treatment of various types of cancers.
• Infectious Diseases: RNA-based therapies targeting viral or bacterial infections fall under this segment.
• Genetic Disorders: This segment encompasses therapies targeting inherited or genetic disorders caused by mutations or abnormalities in specific genes.
• Cardiovascular Diseases: RNA-based therapeutics aimed at treating cardiovascular diseases, such as heart failure or genetic cardiac disorders, belong to this segment.
• Neurodegenerative Diseases: Therapies targeting neurodegenerative disorders, such as Alzheimer’s, Parkinson’s, or Huntington’s disease, fall into this segment.
• Rare Diseases: This segment includes RNA-based therapies developed for rare diseases that have a low prevalence in the population.
• Other Applications: RNA-based therapeutics targeting autoimmune disorders, respiratory diseases, and other therapeutic areas can be categorized under this segment.

End User:

• Hospitals and Clinics: RNA-based therapeutics administered in healthcare facilities, including hospitals and clinics, are included in this segment.
• Research Institutes: This segment comprises RNA-based therapies utilized in research settings or academic institutions for preclinical or clinical studies.
• Pharmaceutical and Biotechnology Companies: RNA-based therapies developed and commercialized by pharmaceutical and biotech companies fall into this segment.

Geography:

The market can be segmented based on geographic regions such as North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. Each region may have different market dynamics, regulatory frameworks, and levels of adoption for RNA-based therapeutics.

These segmentation approaches provide a framework to categorize the RNA-based therapeutic market based on therapeutic modality, application, end user, and geography. It’s important to note that the specific segments may evolve over time as the market matures and new therapies emerge.

Request for Customization – 

https://www.alliedmarketresearch.com/request-for-customization/546

Regional Growth Dynamics:

By region, the market across North America dominated in 2020, garnering more than two-fifths the global RNA based therapeutics market. High expenditure on R&D, presence of major players & their product availability, and well-established healthcare infrastructure in the region propel the market growth. Simultaneously, the Asia-Pacific region is also expected to cite the fastest CAGR of 18.9% throughout the forecast period. This is attributed to improvements in R&D facilities, available disposable income, and rapidly developing economic conditions.

Key players in the industry-

• Silence Therapeutics plc.
• Arbutus Biopharma Corporation
• Ionis Pharmaceuticals
• Sarepta Therapeutics
• Alnylam Pharmaceuticals, Inc.
• Benitec Biopharma Inc.
• Genzyme (Sanofi), Arrowhead Pharmaceuticals
• Biogen, Inc.
• Gradalis, Inc.

Related Reports :

Body Composition Analyzers Market: https://www.alliedmarketresearch.com/body-composition-analyzers-market

Syringes Market: https://www.alliedmarketresearch.com/syringes-market-A07514

Medical Aesthetic Devices Market: https://www.alliedmarketresearch.com/medical-aesthetics-market

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:

help@alliedmarketresearch.com

Web: www.alliedmarketresearch.com

Allied Market Research Blog: https://blog.alliedmarketresearch.com 

Follow Us on | Facebook | LinkedIn | YouTube |